Ligand Pharmaceuticals Inc (LGND) delivered better-than-expected financial results for the third quarter of fiscal 2025. The company reported earnings per share (EPS) of $3.09, significantly surpassing Wall Street's consensus estimate of $1.96 by $1.13. Revenue matched expectations at $0.1 billion, indicating stable operational performance.
The announcement highlights Ligand's ongoing strength in the biopharmaceutical sector, where it develops and acquires technologies to assist pharmaceutical companies in discovering and developing medicines. Headquartered in Jupiter, Florida, Ligand operates with a market capitalization of $3,967.91 and employs 68 full-time staff. Its innovative platforms, including Captisol and NITRICIL, have facilitated the development of several FDA-approved products.
Management will host an earnings conference call to discuss the results and provide further insights into the company's performance and future outlook. Investors are encouraged to review the full earnings release and listen to management commentary for a complete understanding of the quarter's results.
Looking ahead, Ligand Pharmaceuticals is set to announce its next earnings on May 5, 2026, with an estimated EPS of $1.57 and revenue expectations of $0.1 billion.